Roche Investor Relations
ASCO Planner 2014
Friday, May 30

Session Title: Lymphoma and Plasma Cell Disorders
Session Type: Poster Highlights Session
Date: Fri, May 30
Location: S405
Time: 1:00 PM - 4:00 PM
Chair and/or Co-Chairs: Steven M. Horwitz, MD, and Sagar Lonial, MD

- Poster Board: #2
  Phase I study of ABT-199 (GDC-0199) in patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL): Responses observed in diffuse large B-cell (DLBCL) and follicular lymphoma (FL) at higher cohort doses. (Abstract #8522)
  Matthew Steven Davids

Session Title: Developmental Therapeutics: Clinical Pharmacology and Experimental Therapeutics
Session Type: Poster Highlights Session
Date: Fri, May 30
Location: E354b
Time: 1:00 PM - 4:00 PM
Chair and/or Co-Chairs: Luis A. Diaz, MD, and Thehang H. Luu, MD

- Poster Board: #40
  Results from the first-in-human (FIH) phase I study of RO5520985 (RG7221), a novel bispecific human anti-ANG-2/anti-VEGF-A antibody, administered as an intravenous infusion to patients with advanced solid tumors. (Abstract #2525)
  Manuel Hidalgo

Saturday, May 31

Session Title: Targeted Therapies in Early, Mid, and Late Development
Session Type: Clinical Science Symposium
Date: Sat, May 31
Location: E Arie Crown Theater
Time: 1:15 PM - 2:45 PM
Chair and/or Co-Chairs: Andrew D. Zelenetz, MD, PhD, and Michael E. Williams, MD

- 1:39 PM - 1:51 PM
  Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL). (Abstract #8519)
  Franck Morschhauser

- 1:51 PM - 2:03 PM
  Antibody Drug Conjugates as Therapies for Lymphomas
  Ronald Levy
Session Title: Leukemia, Myelodysplasia, and Transplantation
Session Type: Poster Highlights Session
Date: Sat, May 31
Location: S405
Time: 1:15 PM - 4:15 PM
Chair and/or Co-Chairs: Ronan T. Swords, MD, and Hongtao Liu, MD, PhD

- **Poster Board: #5**
  ABT-199 (GDC-0199) combined with rituximab (R) in patients (pts) with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL): Interim results of a phase 1b study. (Abstract #7013)
  Shuo Ma

- **Poster Board: #7**
  ABT-199 (GDC-0199) in relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL): High complete-response rate and durable disease control. (Abstract #7015)
  John Francis Seymour

---

Session Title: Lung Cancer - Non-small Cell Metastatic
Session Type: General Poster Session
Date: Sat, May 31
Location: S Hall A2
Time: 1:15 PM - 5:00 PM

- **Poster Board: #284**
  Antitumor activity of alectinib (CH5424802/RO5424802) for ALK-rearranged NSCLC with or without prior crizotinib treatment in bioequivalence study. (Abstract #8103)
  Kazuhiko Nakagawa

- **Poster Board: #301B**
  Clinical trials of MPDL3280A (anti-PD-L1) in patients (pts) with non-small cell lung cancer (NSCLC). (Abstract #TPS0123)
  Naiyer A. Rizvi

---

Session Title: Unleashing the Immune System in Genitourinary Cancers
Session Type: Clinical Science Symposium
Date: Sat, May 31
Location: E Arie Crown Theater
Time: 3:00 PM - 4:30 PM
Chair and/or Co-Chairs: Sumanta K. Pal, MD

- **3:36 PM - 3:48 PM**
  Inhibition of PD-L1 by MPDL3280A and clinical activity in pts with metastatic urothelial bladder cancer (UBC). (Abstract #5011)
  Thomas Powles

- **4:00 PM - 4:12 PM**
  PD-1/PD-L1 Inhibition: Identifying Relevant Biomarkers
  Padmanee Sharma

- **4:12 PM - 4:30 PM**
  Panel Question and Answer
  Panel Discussion
**Sunday, June 1**

**Session Title:** Sarcoma  
**Session Type:** Oral Abstract Session  
**Date:** Sun, Jun 1  
**Location:** S406  
**Time:** 8:00 AM - 11:00 AM  
**Chair and/or Co-Chairs:** Hussein A. Tawbi, MD, PhD, and Roberta Sanfilippo, MD

- **9:12 AM - 9:24 AM**  
  Phase 1 study of RG7155, a novel anti-CSF1R antibody, in patients with locally advanced pigmented villonodular synovitis (PVNS). (Abstract #10504^)  
  Philippe Alexandre Cassier

**Session Title:** Immunobiology and Immunotherapy  
**Session Type:** Clinical Science Symposium  
**Date:** Sun, Jun 1  
**Location:** S100bc  
**Time:** 11:30 AM - 1:00 PM  
**Chair and/or Co-Chairs:** Robert L. Ferris, MD, PhD

- **11:30 AM - 11:45 AM**  
  Correlation of T-cell inflamed phenotype with mesenchymal subtype, expression of PD-L1, and other immune checkpoints in head and neck cancer. (Abstract #6009)  
  Vassiliki Saloura

**Session Title:** Plenary Session Including the Science of Oncology Award and Lecture  
**Session Type:** Plenary Session  
**Date:** Sun, Jun 1  
**Location:** N Hall B1  
**Time:** 1:00 PM - 4:00 PM  
**Chair and/or Co-Chairs:** Clifford A. Hudis, MD, FACP, and Jedd D. Wolchok, MD, PhD

- **2:45 PM - 3:00 PM**  
  CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). (Abstract #LBA3)  
  Alan P. Venook
- **3:00 PM - 3:15 PM**  
  Discussion  
  Josep Tabernero

**6.00pm-8.00 PM**

**Roche Analyst Meeting**

Marriott Downtown Chicago  
Chicago A-D (Level 5)  
540 North Michigan Avenue  
60611 Chicago
Monday, June 2

Session Title: Lung Cancer - Non-small Cell Metastatic
Session Type: Oral Abstract Session
Date: Mon, Jun 2
Location: E Hall D2
Time: 3:00 PM - 6:00 PM
Chair and/or Co-Chairs: Grace K. Dy, MD, and Egbert F. Smit, MD, PhD

- **3:00 PM - 3:12 PM**
  Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebo-controlled METLung (OAM4971g) global trial.
  (Abstract #8000)
  David R. Spigel

- **3:24 PM - 3:36 PM**
  Two Faces of MET
  Federico Cappuzzo

- **3:36 PM - 3:48 PM**
  Panel Question and Answer
  Panel Discussion

- **4:12 PM - 4:24 PM**
  Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation–positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial.
  (Abstract #8005)
  Terufumi Kato

Session Title: Melanoma/Skin Cancers
Session Type: Oral Abstract Session
Date: Mon, Jun 2
Location: E Arie Crown Theater
Time: 3:00 PM - 6:00 PM
Chair and/or Co-Chairs: Jason J. Luke, MD, and Georgina V. Long, MD, PhD

- **4:36 PM - 4:48 PM**
  Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma. (Abstract #9006^)
  Grant A. McArthur